⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CADL News
Candel Therapeutics, Inc. Common Stock
Candel Therapeutics to Present at November Investor Conferences
globenewswire.com
CADL
Candel Therapeutics Appoints Maria Ostrovsky as General Counsel
globenewswire.com
CADL
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
globenewswire.com
CADL
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CADL
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate
globenewswire.com
CADL
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
globenewswire.com
CADL
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
globenewswire.com
CADL
Form 8-K
sec.gov
CADL
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
globenewswire.com
CADL
Form 8-K
sec.gov
CADL